Inventiva (NASDAQ:IVA) Shares Up 5.7% – Should You Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price was up 5.7% on Wednesday. The stock traded as high as $3.39 and last traded at $3.4450. Approximately 666,986 shares traded hands during mid-day trading, a decline of 32% from the average daily volume of 977,604 shares. The stock had previously closed at $3.26.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IVA. Truist Financial raised their price objective on Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Guggenheim upped their target price on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Wall Street Zen raised shares of Inventiva from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. Piper Sandler restated an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Finally, Cantor Fitzgerald began coverage on shares of Inventiva in a report on Friday, July 17th. They set an “overweight” rating for the company. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Inventiva currently has an average rating of “Buy” and an average price target of $15.86.

Inventiva Price Performance

The company has a 50-day moving average price of $3.98 and a two-hundred day moving average price of $4.43.

Inventiva (NASDAQ:IVA) last announced its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million during the quarter. On average, research analysts predict that Inventiva S.A. Sponsored ADR will post -0.81 earnings per share for the current year.

Institutional Trading of Inventiva

Several large investors have recently modified their holdings of the stock. Platt Investment Counsel LLC bought a new position in shares of Inventiva during the 3rd quarter worth about $45,000. Engineers Gate Manager LP boosted its holdings in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after acquiring an additional 43,280 shares in the last quarter. Finally, Seven Fleet Capital Management LP bought a new position in Inventiva in the first quarter worth approximately $1,111,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.